Overview

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda in Multiple Resected Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-27

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).

Phase:

PHASE1

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

pembrolizumab